FDA's selective disclosure

WASHINGTON - When FDA posted its review of Maxim Pharmaceuticals Inc.'s Maxamine on the Internet on Tuesday, it provided the first public indication that the agency would express serious concerns about the company's NDA at an Oncologic Drugs Advisory Committee (ODAC) meeting the following day.

FDA's analysis sent MAXM shares into a tailspin; Tuesday's 44 percent sell-off was

Read the full 588 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers